Angiotensin III: The Overlooked Blood Pressure Peptide That May Be as Important as Angiotensin II

Angiotensin III is not just a breakdown product of angiotensin II — it's a physiologically active peptide that produces comparable effects on blood pressure, fluid balance, and cardiovascular disease.

Yugandhar, Vudhya G et al.·Peptides·2013·Moderate EvidenceReview
RPEP-02308ReviewModerate Evidence2013RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
Review of research across animal and human studies
Participants
Review of research across animal and human studies

What This Study Found

Angiotensin III (Ang III), long considered a minor degradation product of angiotensin II, actually produces physiologically relevant effects comparable to Ang II. The review establishes that Ang III is a biologically active peptide in its own right within the renin-angiotensin system (RAS), with its own spectrum of effects on blood pressure, blood volume, sodium handling, thirst, and vasopressin release.

The RAS contains multiple active peptides — angiotensinogen, Ang II, Ang III, Ang IV, and Ang-(1-7) — each with distinct physiological roles. While research has overwhelmingly focused on Ang II, emerging data shows Ang III may be equally important in driving the pathological effects seen in heart failure, hypertension, heart attack, and diabetic kidney disease.

Key Numbers

Review covers: AGT, Ang II, Ang III, Ang IV, Ang-(1-7) · Diseases: heart failure, hypertension, MI, diabetic nephropathy · Multiple receptor types and signal transduction mechanisms

How They Did This

This is a narrative review synthesizing published research on angiotensin III's physiological effects across multiple organ systems. The authors compiled evidence from animal studies, cell-based experiments, and clinical observations to build a comprehensive picture of Ang III's role within the RAS.

Why This Research Matters

The renin-angiotensin system is one of the most important drug targets in medicine — ACE inhibitors and ARBs are among the most widely prescribed medications. Yet most research has focused almost exclusively on angiotensin II. Recognizing Ang III as a physiologically relevant peptide opens new therapeutic possibilities and may explain why some patients don't respond fully to current RAAS-targeting drugs.

The Bigger Picture

The renin-angiotensin system is far more complex than the simple angiotensinogen → Ang I → Ang II pathway taught in textbooks. Ang III, Ang IV, and Ang-(1-7) each have distinct biological roles. As this complexity becomes better understood, it could lead to more precisely targeted therapies — for example, drugs that block Ang III specifically while preserving beneficial effects of other angiotensin peptides.

What This Study Doesn't Tell Us

As a narrative review, it does not follow systematic review methodology and may not capture all available evidence. Much of the Ang III data comes from animal studies, and the relative contribution of Ang III versus Ang II in human disease is still being defined. The review does not provide quantitative comparisons of potency between the angiotensin peptides.

Questions This Raises

  • ?Should blood pressure medications be designed to target angiotensin III as well as angiotensin II?
  • ?Does angiotensin III play a larger role in certain diseases (like diabetic nephropathy) compared to angiotensin II?
  • ?Could angiotensin III levels serve as an additional biomarker for cardiovascular risk assessment?

Trust & Context

Key Stat:
Comparable to Ang II Angiotensin III produces physiologically relevant effects similar to angiotensin II on blood pressure, blood volume, sodium handling, and disease pathology
Evidence Grade:
This is a narrative review that synthesizes a broad body of research on Ang III. It provides a comprehensive overview but does not present new data or follow systematic review methodology.
Study Age:
Published in 2013, this review remains relevant as a foundational reference for understanding angiotensin III. The broader RAS peptide field continues to expand, with recent work on Ang-(1-7) and other fragments further supporting the multi-peptide complexity described here.
Original Title:
Angiotensin III: a physiological relevant peptide of the renin angiotensin system.
Published In:
Peptides, 46, 26-32 (2013)
Database ID:
RPEP-02308

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

What's the difference between angiotensin II and angiotensin III?

Angiotensin III is created when an enzyme clips one amino acid off of angiotensin II. Despite being slightly shorter, Ang III produces many of the same effects — raising blood pressure, promoting sodium retention, and stimulating thirst. It's been treated as a minor breakdown product, but this review argues it's a major player in its own right.

Do current blood pressure medications block angiotensin III?

ACE inhibitors reduce Ang III indirectly by blocking the production of its precursor (Ang II). ARBs block the AT1 receptor, which both Ang II and Ang III act on. However, Ang III can be produced through alternative pathways, which may explain why some patients have incomplete blood pressure control.

Read More on RethinkPeptides

Cite This Study

RPEP-02308·https://rethinkpeptides.com/research/RPEP-02308

APA

Yugandhar, Vudhya G; Clark, Michelle A. (2013). Angiotensin III: a physiological relevant peptide of the renin angiotensin system.. Peptides, 46, 26-32. https://doi.org/10.1016/j.peptides.2013.04.014

MLA

Yugandhar, Vudhya G, et al. "Angiotensin III: a physiological relevant peptide of the renin angiotensin system.." Peptides, 2013. https://doi.org/10.1016/j.peptides.2013.04.014

RethinkPeptides

RethinkPeptides Research Database. "Angiotensin III: a physiological relevant peptide of the ren..." RPEP-02308. Retrieved from https://rethinkpeptides.com/research/yugandhar-2013-angiotensin-iii-a-physiological

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.